Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Cytokinetics, Inc.    CYTK   US23282W1009

CYTOKINETICS, INC. (CYTK)

8
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CYTOKINETICS : Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

08/19/2011 | 08:40am US/Eastern
Results from These Trials Form the Basis For Ongoing Phase IIb Activities in Collaboration with Amgen

South San Francisco, CA - August 19, 2011

omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability, pharmacokinetics and pharmacodynamic effects of this investigational drug candidate from a Phase I first-time-in-humans clinical trial in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients, each sponsored by Cytokinetics. Together, these publications provide evidence for the translation into humans of this unique mechanistic approach to activating cardiac muscle contractility and support the further development of omecamtiv mecarbil as a potential treatment for heart failure. Amgen Inc. holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.

React to this article
Latest news on CYTOKINETICS, INC.
06/20 CYTOKINETICS : Presents Results From Phase I Studies of CK-2127107
06/19 Cytokinetics Presents Results From Phase I Studies of CK-2127107
06/17 CYTOKINETICS : to Present at the 9th Annual JMP Securities Life Sciences Confere..
06/16 Cytokinetics to Present at the 9th Annual JMP Securities Life Sciences Confer..
06/11 Cytokinetics Announces Poster Presentation on CK-2127107 at the 19th Internat..
06/05 CYTOKINETICS : and The ALS Association Announce Partnership to Advance the Fight..
06/04 Cytokinetics and The ALS Association Announce Partnership to Advance the Figh..
06/04 CYTOKINETICS : And The ALS Association Announce Partnership To Advance The Fight..
05/21 CYTOKINETICS : Submission of Matters to a Vote of Security Holders (form 8-K)
05/13 CYTOKINETICS : to Hold Annual Meeting of Stockholders
Advertisement
Income Statement Evolution
More Financials